We have comprehensively evaluated the somatic mutation landscape of WNT signaling regulators in serrated colorectal cancers. We identified a mosaic of mutations that may be responsible for elevating WNT signaling in this context. Approximately 20% of serrated colorectal cancers harbor truncating APC mutation, and these cancers confer extremely poor prognoses.
Background
Colorectal cancer is a heterogeneous disease that arises through two main molecular pathways. The conventional pathway, which accounts for 75-80% of all colorectal cancer diagnoses, is initiated by biallelic inactivation of APC and progresses to cancer via mutations in KRAS and alterations to the TP53 gene. By contrast, the serrated neoplasia pathway is initiated by activating mutations in BRAF and often progresses to malignancy via MLH1 hypermethylation, microsatellite instability and a plethora of epigenetic alterations. At the transition to dysplasia, serrated lesions usually acquire mutations that increase WNT signaling. Sessile serrated lesions (SSLs) acquire missense APC mutations 1 , and truncating RNF43 mutations 2 . In traditional serrated adenomas (TSAs), common WNT pathway aberrations include RSPO3 fusions 3,4 , mutations of CTNNB1 3 and mutation of APC 3 .
In the normal enterocytes the WNT signaling cascade exists to support stemness, differentiation and development. Appropriate levels of WNT signal are maintained intracellularly by the β catenin destruction complex. The complex consists of AXIN, APC, GSK3β, and CK1α. The destruction complex ubiquitinates β -catenin in the cytosol, triggering its subsequent proteasomal degradation. In the absence of the destruction complex, β -catenin translocates to the nucleus, forms a complex with the TCF/LEF molecules and p300 to activate the expression of genes supporting the stem phenotype. Constitutive WNT signaling is deleterious to the cell and thus in the absence of exogenous stimuli the β -catenin destruction complex patrols the cytosol and degrades β -catenin. WNT signaling is activated by the binding of extracellular WNT ligands to frizzled receptors residing on the cell surface. This triggers the sequestering of the destruction complex to the cell membrane and facilitates the build-up of β -catenin, which enters the nucleus and activates WNT target genes.
Approximately 45-50% of BRAF mutant cancers show dysregulated WNT signaling 1 , and thus the WNT signaling pathway appears important to serrated colorectal neoplasia. In conventional colorectal carcinogenesis, WNT signaling is dysregulated via truncating mutations of APC and loss of 5q21, the region where the APC gene resides 5 . This dysregulation occurs very early in the evolution of conventional adenomas. However numerous studies have indicated that mutation of BRAF is almost never identified in such APC mutated adenomas even when they develop advanced histological features 6, 7 . This suggests that BRAF and APC mutations are mutually exclusive in conventional adenomas.
In the serrated neoplastic pathway where the initiating mutation is BRAF, WNT signaling only commonly becomes dysregulated when the benign polyp transitions to malignancy. Truncating RNF43 mutations may alter WNT signaling, but these are predominantly present in mismatch repair deficient BRAF mutant cancers 2, 8 , and there is controversy as to whether RNF43 mutation affects canonical WNT signaling 9 . Epigenetic silencing of WNT pathway members is another possible mechanism for altering canonical WNT pathway activity. Methylation of SFRP genes increases WNT signaling 10 and is common in colorectal cancer 11 . Similarly DNA methylation induced inactivation of DKK genes, which are antagonists of WNT signaling, occurs in ~20% of all colon cancers 12 . The frequency of WNT signaling dysregulation being due to APC mutation is not well established.
Here we have conducted a large-scale genomic analysis of the somatic mutations that underlie WNT signaling activation in BRAF mutant colorectal cancer. We hypothesise that WNT signaling activation in BRAF mutant cancers will be heterogeneous, and a mosaic of alterations underpin WNT signaling to achieve a "just-right" level of pathway activation.
Methods

Cohorts included in the study
We assessed the somatic mutational landscape of 199 BRAF mutant cancers from four distinct sources. This included cancers from The Cancer Genome Atlas project (n=51) 7, 13 , the Dana Faber Cancer Institute (Giannakis et al 2016, n=111) 14 , the Clinical Proteomic Tumor Analysis Consortium (Suhas et al 2019, n=13) 15 and additional BRAF mutant cancers that were sequenced as part of this study (methods detailed below, n=24). For analyses involving the APC tumour suppressor gene we included additional targeted sequenced data from the Memorial Sloan-Kettering Cancer Centre (Yaeger et al 2018, n=76) 16 . This dataset was limited to a panel of genes and as such was excluded from other analyses. Supplementary Figure 1 shows similar tumor mutation burden across each cohort. Clinicopathological details of samples included in this study and mutational data are available as supplementary materials ( Supplementary Table S1 and S2).
DNA extraction, library preparation and exome sequencing of local samples
Cancer and germline samples were obtained from patients at the Royal Brisbane and Women's Hospital, Brisbane, Australia at the time of surgery. All participants gave their written, informed consent prior to participating in the study and the study was approved by the QIMR Berghofer Human Research Ethics Committee (P460, P773). DNA was isolated from whole blood using the salt precipitation method as previously reported 17 . Cancer samples were snap-frozen in liquid nitrogen and DNA extracted using the AllPrep DNA/RNA/Protein mini kit (QIAGEN, Germany) as previously reported 18 . Exome-sequencing libraries were generated using the Agilent SureSelect Human All Exon V4+UTR capture platform (Agilent, CA, USA). Libraries were sequenced to a target depth of 200-fold coverage on a 100 bp paired-end sequencing run using an Illumina HiSeq 2000 instrument. Sequence reads were trimmed using Cutadapt (v1.9) 19 and aligned to the GRCh37 reference with BWA-MEM (v0.7.12) 20 . Alignments were duplicate-marked with Picard (v1.129, https://broadinstitute.github.io/picard/) and coordinatesorted using Samtools (v1.1) 21 . Single nucleotide substitution variants were detected using a dual calling strategy using qSNP (v2.0) 22 and the GATK HaplotypeCaller (v3.3-0) 23 . The HaplotypeCaller was also used to call short indels of ≤ 50 bp. Initial read filtering for all variants detected included: a minimum of 35 alignment matches in the CIGAR string, 3 or fewer mismatches in the MD field, and a mapping quality greater than 10. High confidence variants were selected with: a minimum coverage of 8 reads in the control data and 12 reads in the tumour data; at least 5 variant supporting reads present where the variant was not within the first or last 5 bases; at least 4 of the 5 reads with unique start positions; the variant was identified in reads of both sequencing directions; the variant was not less than 5 base pairs from a mono-nucleotide run of 7 or more bases in length. Variants were annotated with gene feature information and transcript or protein consequences using SnpEff (v4.0e) 24 .
Assessing the somatic mutational landscape of WNT regulators
To assess the somatic mutational landscape of WNT signaling regulators we downloaded mutational annotation files for each cohort from the Genome Data Commons (TCGA, ), cBioPortal (CPTAC), from supplementary materials (DFCI) or analysis of the Royal Brisbane and Women's Hospital, Brisbane cases. MAF files concatenated to form a combined MAF file comprised of 924,366 entries relating to 1411 samples. BRAF V600E mutant samples were subset from the larger dataset, yielding a total of 320,431 variants from 199 samples. As we sought to investigator WNT, we further selected only genes that were members of the REACTOME signaling by WNT geneset (n=327 genes). The final dataset was comprised of 5,327 nonsynonymous variants in WNT signaling loci that corresponded to 199 samples. Analysis of variants was performed using the MAFtools R package 25 . Cancer drivers were predicted using two orthogonal approaches (OncodriveClust 26 : Default parameters; OncodriveFML 27 : Scores: CADD v1.3, Signature: Computed by sample, remaining parameters: default). Driver mutation analyses were performed on the entire set of variants to accurately model the background mutational processes. Results from Non-WNT loci were discarded and FDR corrections were performed on the remaining P values that pertain to tests performed on genes in the WNT signaling pathway. Somatic interactions (co-mutations and mutual exclusivity) were identified by performing fishers exact test on pairs of genes.
Murine model of Apc and Braf mutation
To model the effects of Apc and Braf mutation on colorectal neoplasia we utilized two murine models. The Apc Min/+ mouse has a mono-allelic mutation at codon 851 and recapitulates human germline APC mutation. In both humans and mice, progression is governed by the loss of the remaining allele. Our second model, the Braf CA/CA /Villin-Cre ERT2/+ mouse 28, 29 , is an inducible model of Braf mutant colorectal neoplasia. Recombination of the mutant Braf V637E allele is induced at 2 weeks of age by a single intraperitoneal injection of tamoxifen (75mg/kg). The Braf V637E allele is the murine analogue of the BRAF V600E human mutation. To model the effects of Apc mutation and Braf mutation we crossed Apc Min/+ mice with Braf CA/CA /Villin-Cre ERT2/+ . Animals were monitored biweekly for signs of distressed and humanely euthanized when such signs were identified, as per our approved protocol (QIMR Berghofer Animal Ethics Committee; P1208). For survival analysis, animals were deemed to be deceased if they were euthanized due to distress. If animals reached the prescribed endpoints of the experiment without any signs of distress they were deemed to have survived and were censored for survival analysis.
At sacrifice the gastrointestinal tract from oesophagus to rectum was removed, cleaned and opened longitudinally. Macroscopic lesions were bisected to obtain both molecular and histological data. Matched normal hyperplastic tissue was taken minimum five centimetres from the site of the lesion. Histological assessment of lesions and lesion counts was performed on haematoxylin and eosin stained sections from formalin-fixed, paraffin-embedded blocks by specialist gastrointestinal anatomical pathologists.
Sanger Sequencing
Sanger sequencing was performed to assess the G7 repeat track of WNT16. PCR conditions were as follows: 1X GoBuffer (ProMega, USA), 2.5mM MgCl 2 , 0.25mM dNTP, 0.25uM Forward Primer (5' GGCAACATGACAGAGTGTTCC 3'), 0.25uM Reverse Primer (5' GCCATACTGGACATCATCGG 3'), 0.25uM Syto9, 1U GoTaq DNA polymerase (ProMega, USA), 50ng DNA; Cycing: 95 C hold for two minutes, 40X cycles of 95 C for 30 seconds, 60 C for 30 seconds, 72 C for 45 seconds, followed by a 72 C hold for five minutes at the end of cycle 40. Sequencing was performed as per Fennell et al 30 .
Statistical Analysis
All statistical analysis was performed in Microsoft Open R (v3.5.1). Students T-Tests were performed for hypothesis testing of continuous variables. Logistic regression analyses were employed to examine the probability of mutations over patient age. The likelihood-ratio test was performed to assess associations with categorical variables and fishers exact test to examine for mutual exclusivity of mutations in gene-pairs.
Results
The somatic mutation landscape of WNT signaling in BRAF mutated cancers
To assess the degree of variation in genetic alterations of WNT signaling pathway genes, we collated whole exome-sequencing data of BRAF mutant colorectal cancers from three previously published studies 7, 14, 15 , combined with 24 samples that were sequenced in-house (total n=199). We limited WXS variants to genes in the WNT signaling cascade, as identified in the REACTOME signaling by WNT gene set (n=327 genes). The mean number of WNT pathway mutations per sample was 16.7±13.6, and was highly correlated with overall tumour mutation burden (P= 4.08x10 -85 , r 2 =0.86). RNF43 was the most commonly mutated gene (41%, Figure 1 ). 35.3% of samples had a truncating mutation in RNF43. KMT2D, TRRAP, and APC were mutated in 33%, 30% and 28% of samples, respectively ( Figure 1 ). The β -catenin destruction complex is an important regulator of canonical WNT signaling. It is comprised of APC, AXIN1, AXIN2, and GSK3β ( Figure 2 ). We next evaluated how frequently mutations occur in any component of this complex or in CTNNB1 itself. 48% of all cancers had mutations in at least one of these five genes. Mutations in APC and AXIN2, but not AXIN1, are significantly mutually exclusive (P<0.05). Missense mutations in CTNNB1 have been reported to render the molecule impervious to ubiquitin-mediated destruction. CTNNB1 mutations occur in 9% of samples. Missense CTNNB1 mutations were mutually exclusive with truncating APC mutations.
Somatic mutation interaction analysis identifies co-mutated WNT signaling loci and mutual exclusivity of truncating APC and RNF43 mutations
We performed somatic mutation interaction analyses to examine for mutations in genes that are mutually exclusive and those that tend to co-occur. We found evidence for co-occurring mutations in 222 gene pairs ( Figure 3 ). Table 1 summarizes the top 20 pairs of genes, which have co-occurring mutations. As truncating mutations are more likely to influence the final protein, we next examined somatic interactions between truncating mutations in WNT pathway genes ( Figure 3 ). We identified statistical evidence for somatic interactions between 75 gene pairs. 96% were between co-mutated gene pairs (Supplementary Table S3 , Table 1 ). Truncating APC mutation was mutually exclusive to truncating mutations in both RNF43 (P0.0003, OR:0.20), and ZNRF3 (P=0.001, OR: 0). AMER1 truncating mutations were mutually exclusive to RNF43 mutation (P=0.043, OR:0.12).
Mutation clustering analysis reveals mutational hotspots in nine WNT signaling genes
We next sought to identify driver genes using the OncodriveCLUST algorithm. This method identifies potential driver genes using a positional clustering method and operates on the assumption that clusters of mutations, or "mutational hotspots" are more likely to occur in oncogenes. In keeping with previous studies 2,8,30,31(p43) , RNF43 was identified as a putative cancer driver (P=0.07). Somatic mutations in MEN1, a gene identified as a familial cancer risk gene and as an inducer of genome wide hypermethylation, were identified as putative drivers. MEN1 was mutated in 4% (8/199, P<0.001) of samples, and most of the identified mutations were frameshift deletions at R521. Moreover, WNT16 was implicated as a potential cancer driver (P=0.06). WNT16 harbours a mutational hotspot at G165. This codon resides in a G7 repeat track that was the subject of frameshift indels in 15 cancers ( Table 2 ). We used Sanger sequencing to orthogonally validate the presence of WNT16 hotspot mutations in BRAF mutant cancers (n=79) and identified frameshift mutations in 20.2% (16/79) of cancers (Supplementary Figure S2 ).
We used oncodriveFML, an orthogonal computational method of predicting cancer drivers based on predictions of functionality, to identify other potential driver genes that do not necessarily harbour clusters of mutations. This analysis identified 11 potential cancers drivers in the WNT signaling cascade, three of which were identified by oncodriveCLUST (RNF43: P=7.22x10 -6 , MEN1: P= 0.02, and GNG12: P=0.012). Other genes that were identified include members of the beta-catenin destruction complex (APC: P=7.22x10 -6 , AXIN1: P<0.01, AXIN2: P=0.0001), ZNRF3 (P=7.22x10 -6 ), SOX9 (P=7.22x10 -6 ), BCL9L (P<0.001), PYGO2 (P<0.001), and WNT11 (P=0.045).
Co-mutation of APC and BRAF represents a unique and aggressive subtype of BRAF mutant cancers
We next evaluated the relationship between BRAF mutation and APC mutation in further detail to characterize the clinical and molecular correlates of this subtype of cancers. We supplemented the 199 BRAF mutant exomes assessed earlier in the manuscript with 76 BRAF mutant cancers that were subjected to targeted sequencing as part of Yaeger et al 2018 16 .
Truncating mutation was present in 20% of BRAF mutant cancers. We examined whether there was a relationship between age at diagnosis and APC mutation by logistic regression analysis. The probability of truncating APC mutation occurring in a BRAF mutant cancer decreases markedly with age from ~60% in patients diagnosed at age 40, to <10% of patients diagnosed at >90 years of age (Logistic Regression P=3.74x10 -7 ). The average age of patients with a BRAF V600E /APC Truncated cancer was significantly lower than both patients with a BRAF V600E /APC Missense tumour (61 vs 72, P=2.03x10 -5 , Table 3 ) and a patient with a BRAF V600E /APC Wild-type cancer (61 vs 71, P=9.3x10 -6 ). BRAF V600E /APC Truncated cancers were more likely to be left sided when compared with BRAF V600E /APC Missense cancer (24.5% vs 4.2%, P=0.02, Table 3 ). There was no difference in frequency of CIMP versus either missense or wild-type APC cancers. 42.3% of BRAF V600E /APC Truncated cancers were microsatellite unstable. MSI is less frequent than both BRAF V600E /APC Missense (91.3%, P=5.3x10 -5 , Table 3 ) and BRAF V600E /APC Wild-type (53.8%, P=0.14) cancers. BRAF V600E /APC Truncated cancers were aggressive cancers, with 67.3% of patients presenting with metastatic disease. In contrast, only 36.4% and 45.7% of BRAF V600E /APC Missense and BRAF V600E /APC Wild-type cancers presented at stage III/IV (P= 0.01 and 0.002 versus BRAF V600E /APC Truncated , respectively). BRAF V600E /APC Truncated cancers that were also microsatellite stable were enriched further for late-stage disease, with 100% of these patients presenting with metastatic disease (Stage III or IV), and 88% with distant metastases (Stage IV).
Furthermore, univariable analysis of survival indicated that BRAF V600E /APC Truncated cancers have a significantly poorer median survival (504 days vs 1390 days, Log-rank P=0.026, n=32 and n=78 for truncating mutant and wild-type, respectively; Figure 4A ). The five-year survival of BRAF V600E /APC Truncated patients was 12%. By contrast the five year survival of BRAF V600E /APC Wild-Type patients was 42%. We performed multivariate survival analysis, including age at diagnoses, gender, stage and microsatellite instability as potential prognosticators. Using the cox-proportional hazard method, microsatellite instability status, and gender are significantly independently associated with survival. Truncating APC mutation trends toward conferring independent negative prognostic implications, however this failed to reach the threshold for significance ( Table 4 , P=0.17). Collectively these data indicate that activating mutation of BRAF and truncating mutation of APC represent an aggressive subtype of colorectal cancers that occur at a relatively young age in comparison to BRAF mutant cancers more generally.
Mutation of Braf in APC min/+ mouse results in massive polyp load, rapid disease progression and poor survival
To determine if we could recapitulate the apparently aggressive phenotype of co-mutation of BRAF and APC we crossed inducible Braf V637 mutant mice with Apc min/+ mice. The Braf mutation was induced at wean in Apc Min/+ mice and we compared the number of lesions per animal and survival to mice with just the mutant Braf allele or the mutant Apc allele.
We next assessed differences in survival between Apc Min/+ (n=29), Braf V637 (n=15), and APC Min/+ / Braf V637 mice (n=22). Animals were regarded as having survived and were censored if they were healthy at the time of sacrifice, animals regarded as deceased if the animal had to be euthanized due to illness. 100% of Braf mutant animals survived to 12 months, as did 81.25% of Apc mutant animals. Mutation of both Braf and Apc significantly reduced the survival of the animals (P= 8.8x10 -21 , Figure 4B ). The median survival of animals with both Apc and Braf mutation was 3.2 months. No animal with both mutations survived longer than six months.
We assessed polyp load by microscopic enumeration. Animals with Braf and Apc mutations alone develop an average of 4.6 and 16.55 polyps in the small intestine, respectively. Animals with both Braf and Apc mutation simultaneously develop significantly more lesions in the SI (P<0.0001, Figure 5A ). Animals with Braf or Apc mutation rarely developed colonic or caecal lesions (mean lesions per mouse: 0.11 and 1.1, respectively, Figure 5B ). In contrast, dual mutation of Apc and Braf resulted in the accumulation of an average of 59.82 colonic/caecal lesions per animal (P<0.0001, Figure 5B ). We did not observe a significant increase in lesion size in the small intestine between groups, however we did observe significantly larger lesions in the colon and caecum of animals bearing both Apc and Braf mutation (P<0.0001, Figure 5C ). Lesions had a morphology that was reminiscent of human conventional adenomas, rather than dysplastic serrated lesions.
Discussion
Here we have investigated the role of somatic mutation in shaping the WNT signaling landscape of colorectal cancers bearing the BRAF mutation. We have shown that 48% of BRAF mutant cancers mutate at least one member of the B-catenin destruction complex. Other common modes of activation including mutation of RNF43 and ZNRF3. We have identified a number of novel mutations that may alter the WNT signaling landscape of cancers. These include MEN1, a known WNT pathway tumour suppressor, and WNT16, a WNT ligand that may act as an antagonist of ligand mediated WNT activation. Both MEN1 and WNT16 harbour hotspot frameshift mutations that were identified as potential drivers by computational analysis. Mutation of RNF43 was mutually exclusive to mutation of APC. We examined the clinical and molecular correlates of BRAF mutant cancers bearing truncating mutations of APC, which occurred in 20% of samples. These cancers were predominantly microsatellite stable, and late stage. Cancers with a truncating APC mutation occurred at an average age that was >10 years lower than the wider cohort of BRAF mutant cancers. Survival analysis revealed a significantly poorer prognosis for this subtype of patients. Using murine models of Apc and Braf mutation, we show that mutating both genes results in an extensive phenotype with massive lesion burden. Animals had a median survival of 3.2 months, and no animal bearing both mutations survived longer than 6 months. Collectively these data indicate that mutation of both BRAF and APC results in an aggressive and rapidly progressing cancer phenotype and confers a poor prognosis.
WNT signaling underpins colorectal carcinogenesis. In the conventional pathway WNT signaling is usually activated via bi-allelic inactivation of the APC tumour suppressor gene at the beginning of the tumourigenic process. However, the mechanisms governing WNT pathway activation in the serrated neoplasia pathway, which is uniquely marked by BRAF mutation, is less clear. In the present study, we sought to identify WNT signaling genes that are mutated in the context of BRAF mutant serrated colorectal neoplasia. We obtained exome sequencing data from 175 BRAF mutant colorectal cancers from four previously published studies 7, 14, 15, 32 and sequenced a further 24 BRAF mutant samples collected locally. Our analyses revealed a mosaic of mutations in WNT signaling regulators, including well-known WNT regulators such as RNF43, APC, AXIN2 and ZNRF3. Our analysis identified significant mutual exclusivity between truncating mutations of RNF43 and APC. Likewise, ZNRF3 mutation was mutually exclusive to truncating mutations of APC. This association was present only when missense mutations were not included. It is possible that the addition of a truncating APC mutation in this context is disadvantageous to tumour progression. Therefore, mutation of RNF43/ZNRF3 may create a genetic dependency on APC. If true, exploiting the dependency on APC, a canonical tumour suppressor gene, may be a novel therapeutic treatment for patients with an RNF43 mutated cancer.
We next examined the exome sequencing data to identify potential novel drivers of WNT signaling activation in colorectal cancer. We adopted a mutational clustering based approach to identify potential cancer drivers based on the presence of mutational hotspots, as implemented in the oncodriveCLUST algorithm 26 . Reassuringly, RNF43, which has two mutational hotspots 2, 8, 30 was successfully identified as a cancer driver. RSPO fusions, which have been implicated in WNT dysregulation of serrated lesions and cancers 4,33 , were not identified due to technological limitations. It is likely that some cancers in this cohort harboured such fusions given the frequency of RSPO fusions previously reported. We identified eleven other potential cancer driver genes in the WNT signaling cascade. MEN1 was mutated in eight samples and most mutations were frameshift alterations at codon R521. Germline MEN1 mutations result in multiple endocrine neoplasia type 1, a tumour predisposition syndrome. It has also been identified as a tumour suppressor gene in a number of different cancer types, including tumours of the parathyroid 34(p1) , entero-pancreatic neuroendocrine cancers 35(p1) , and carcinoids 36 . Interestingly, especially in the context of highly methylated BRAF mutant cancers, loss of MEN1 has been associated with aberrant DNMT1 activity and an altered DNA methylation landscape. To our knowledge, MEN1 alterations have not been previously reported in colorectal cancer, nor is colorectal cancer a typical presentation of MEN1 syndrome. It is possible these patients had an underlying germline mutation in MEN1, and the mutations identified in this studied were the second hit at the locus.
WNT16 was also identified as a potential cancer driver gene. WNT16 is a WNT ligand, a seemingly unlikely candidate tumour suppressor. However, Nalesso et al 37 showed that while WNT16 was capable of binding Fzd receptors and activating canonical WNT signaling, the degree of activation was significantly lower when compared with the more abundant WNT3A. TOPFlash assays showed that costimulation with both WNT3A and WNT16 resulted in significantly less canonical WNT activation when compared with stimulation using WNT3A alone 37 . Thus, it appears WNT16 acts as a competitive inhibitor of Fzd and acts to ensure the homeostasis of WNT signaling. In cancer, loss of WNT16 may facilitate excessive canonical WNT activation by failure to compete with more potent WNT ligands, such as WNT3A and WNT8. As such, it is likely that WNT16 acts as a tumour suppressor. Inhibitors of WNT ligand secretion, such as porcupine inhibitors, are currently being trialed in colorectal and other solid tumours 38 . Cancers that lack WNT16 are prone to excessive ligand-dependent WNT activation 37(p16) and may represent a subset of patients that could benefit from this therapy. Indeed, as much of WNT16 mutations occur on a background of RNF43 alterations, which has been shown to confer sensitivity to porcupine inhibitors 31 , mutation of both genes could further sensitize cells to this class of drugs. Both functional and biomarker studies are required to determine whether WNT16 has a role in determining sensitivity to WNT-ligand inhibitors.
We recently assessed a series of 80 BRAF mutant cancers 1 and identified truncating APC mutation in 11% of these cancers. It has been postulated that truncating APC mutation is uncommon in the context of pre-existing BRAF mutation because the dysregulation of WNT signal is too profound in this cellular context. This is consistent with the model proposed by Albuquerque et al 39 and indicates that mutations such as RNF43/ZNRF3 provides a "just-right" level of WNT signaling to confer a selective advantage. However, the present study has confirmed that a minority of BRAF mutant cancers do carry a truncating APC mutation. The higher proportion of cancers bearing both APC and BRAF mutation in the present study may be due to selection bias in the present series with a higher proportion of late stage microsatellite stable cancer included.
APC mutations were much more common in minority of BRAF mutant cancers diagnosed at a younger age. The average age of BRAF mutant cancers harbouring APC mutation was 12 years less than APC wild-type. These cancers were more likely to be microsatellite stable, and present with metastatic disease. The median survival of patients with BRAF mutation and APC mutation was 64% lower than patients with BRAF mutation alone, and patients with both mutations had a five-year survival rate of 12%. These cancers appear to be highly aggressive and occur earlier in life. We generated a murine model to recapitulate mutation of APC and BRAF to examine interactions between these mutations and the consequences of mutating both genes on polyp development and overall survival. We observed massive polyp loads in animals bearing both mutations, and a markedly reduced survival. 100% and 81.25% of Braf mutant and Apc mutant animals survived to 12 months. When we mutated both genes, no animals survived past six months and the median survival was reduced to a mere 3.2 months. While animals did not develop invasive cancer, and instead died due to polyp load, these data indicate that comutation of APC and BRAF in an enterocyte induces rapid neoplastic alterations and an overt proliferative phenotype. Collectively these data provide strong evidence that mutation of both APC and BRAF, whilst uncommon in humans, generates a remarkably aggressive neoplastic phenotype.
It is difficult to resolve how these particular cancers have evolved. Both APC and BRAF mutations are tumour-initiating events 28, 40, 41 and give rise to different precursor lesions 42 . Moreover, the cell of origin for APC initiated polyps and BRAF initiated polyps is hypothesized to differ. APC initiated lesions adhere to the "top-down" model 43 , whereas BRAF mutant lesions are initiated in the stem compartment 44 . Methylation profiling of BRAF mutant and APC mutant cancers confirmed this model, and showed that BRAF mutant cancers had a methylation profile reminiscent of the intestinal stem cell 44(p) . In our study, we observed no difference in the frequency of CIMP between BRAF mutants with APC mutation and those without, suggesting that these dual-mutant cancers may have arisen in the stem component, and therefore may have been initiated by BRAF and acquired an APC mutation at a later stage. However it is difficult to reconcile this with the rarity to which APC is mutated in BRAF mutant precursor lesions 1 . It is possible that, upon acquiring an APC mutation, progression to cancer is rapid and as a result identifying lesions in a transitional state is rare. This fits with the aggressive phenotype of these cancers. An alternative hypothesis, supported an age at diagnosis that is similar to conventional pathway cancers 18 and the morphology of our murine adenomas, is that polyps are initiated by APC, acquire a BRAF mutation. If this is the case such lesions must progress extremely rapidly to cancer as they are very rarely identified in large series of conventional adenomas.
In conclusion, here we have conducted a comprehensive survey of the somatic mutational landscape shaping WNT signaling in BRAF mutant serrated colorectal neoplasia. The mutational landscape of WNT signaling regulators is a mosaic that is underpinned by mutations in key driver genes, such as RNF43 and APC. Mutations of RNF43 and APC are mutually exclusive. We identified potential cancer driver genes in the WNT signaling axis. MEN1 has previously been implicated in cancers of endocrine origin, but has not been identified as a tumour suppressor gene in colorectal cancer. We have identified a hotspot mutation in MEN1 that effects 4% of BRAF mutant cancers. We have identified WNT16 as a potential driver gene by mutational hotspot analysis. WNT16 is a competitive inhibitor of canonical WNT and mutation of WNT16 is common in BRAF mutant cancers. Loss of WNT16 may increase the sensitivity of cancers to WNT ligand dependent canonical WNT signaling and thus WNT16 mutant cancers may be susceptible to inhibitors of WNT ligand secretion (ie. PORCN inhibitors). BRAF mutant colorectal cancers with truncating APC mutation tended to arise earlier in life, and presented at a significantly later stage. These cancers are extremely aggressive and survival of patients with both BRAF and APC mutation is poor (12% 5-year survival). In vivo modelling of Apc and Braf mutation revealed a dramatically increased tumour burden with the median survival of 3.2 months for animals with both mutations. Therefore, we conclude that co-mutation of BRAF and APC in colorectal cancers is conducive to an aggressive phenotype. Table 1 : Somatic interaction analysis identifies significantly co-occurring mutations in 222 gene pairs. Analysis of truncating mutations only identified 75 somatic interactions. The twenty most significant interactions are detailed in this table. For the remaining interactions, see Supplementary Table S3 . P Values were calculated using the fishers exact test.
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